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Alternatives for the BedsideACKDSchwartz Equation to
Estimate Glomerular Filtration Rate in Children
Hans Pottel, Laurence Dubourg, Karolien Goffin, and Pierre DelanayeAdv CThebedsideSchwartz equationhas longbeen and still is the recommended equation to estimateglomerular filtration rate (GFR)
in children. However, this equation is probably best suited to estimate GFR in children with chronic kidney disease (reduced
GFR) but is not optimal for children with GFR .75 mL/min/1.73 m2. Moreover, the Schwartz equation requires the height of
the child, information that is usually not available in the clinical laboratory. This makes automatic reporting of estimated
glomerular filtration rate (eGFR) along with serum creatinine impossible. As the majority of children (even children referred
to nephrology clinics) have GFR .75 mL/min/1.73 m2, it might be interesting to evaluate possible alternatives to the bedside
Schwartz equation. The pediatric formof the Full Age Spectrum (FAS) equation offers an alternative to Schwartz, allowing auto-
matic reporting of eGFR since height is not necessary. However, when height is involved in the FAS equation, the equation is
essentially equal to the Schwartz equation for children, but there are large differences for adolescents. Combining standardized
biomarkers increases the prediction performance of eGFR equations for children, reaching P10z 45% and P30z 90%. There are
currently good and simple alternatives to the bedside Schwartz equation, but the more complex equations combining serum
creatinine, serum cystatin C, and height show the highest accuracy and precision.
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Estimating glomerular ﬁltration rate (GFR) in children has
a 40-year-old history, dating back to 1976 when Schwartz
and colleagues1 published his very simple bedside for-
mula eGFR ¼ 0.55 3 L/Scr, where L is the height of the
child and Scr represents serum creatinine (Scr) expressed
in mg/dL. The coefﬁcient of 0.55 has been replaced by
0.413 for children and adolescents, when isotope dilution
mass spectroscopy (IDMS) standardized assays for Scr
became available.2 The height of the child serves as surro-
gate for muscle mass, since creatinine, which is a break-
down product of muscle mass, changes during growth
of the child. The Schwartz formula has been recommended
by KDIGO to estimate GFR in children. One downside of
this equation is the need for the height of the child, which
is commonly not available in the clinical laboratory, mak-
ing automatic reporting of estimated glomerular ﬁltration
rate (eGFR) along with Scr impossible. Automatic report-
ing of eGFR for adults is mandatory in many countries, al-
lowing early identiﬁcation of patients with chronic kidney
disease (CKD), with evidence demonstrating the beneﬁts
of early referrals.3 Indeed, in adults, evidence-based strate-
gies have been shown to prevent progression of CKD.4 The
rationale for automatic reporting in children is less clear,
since there are multiple risk factors, such as hypertension
and proteinuria, for progression of CKD in children.More-
over, the incidence of CKD in children is much lower than
in the adult population. However, early reporting of
decreased eGFR may allow early detection and interven-
tion which can only be to the beneﬁt of the child.
In a recent overview, Pottel5 has extensively reported on
the different eGFR equations for children, and therefore, in
this review, we will focus on alternative equations appli-
cable to (multiple) biomarkers for standardized assays
only. We then give speciﬁc insights comparing the bedside
Schwartz equation with the pediatric part of the Full Age
Spectrum (FAS) equation. Next, we elaborate on the possi-
bility to deﬁne kidney function based on the reference in-hronic Kidney Dis. 2018;25(1):57-66terval of single biomarkers or the combination of
biomarkers, without using eGFR equations. Finally, we
present the prediction performance of eGFR equations
combining multiple (standardized) biomarkers, namely
Scr and serum cystatin C (ScysC), using real measured
GFR data as comparison.
REFERENCE METHOD, STANDARDIZED Scr, AND
CYSTATIN C
The gold standard method to obtain measured GFR
(mGFR) is kidney clearance of inulin, but several reference
methods have shown acceptable accuracy with sufﬁcient
scientiﬁc evidence.6 The mGFR data used in this article
have been obtained by the gold standard inulin kidney
clearance method or by iohexol or 51Cr-EDTA plasma
clearance, using the slope-intercept method followed by
the Br€ochner-Mortensen correction.7
Standardization of Scr assays with reference to the gold
standard IDMS method has been introduced some
10–15 years ago. Most enzymatic Scr assays are nowadays
equivalent to the IDMS method. The data used in this
article were all obtained with IDMS traceable enzymatic
Scr assays, and it should be emphasized that this is57
Pottel et al58critically important for children that have lower Scr values,
requiring high accuracy and precision results.8 Indeed,
compensated Jaffe assaysmay give negative Scr concentra-
tions after compensation (¼ subtracting a constant value)
in very young children. Limits of quantitation of the assays
should be as low as 0.15 mg/dL, since newborns typically
have Scr values of about 0.23 mg/dL 1 month after birth.9
Many clinical laboratories still use the Jaffe-type Scr as-
says instead of enzymatic Scr assays due to the higher
cost of the latter, but the gap becomes smaller and more
and more laboratories switch to enzymatic assays, espe-
cially for children.
The situation is different for ScysC. In 2010, there became
a certiﬁed standard available (ERM-DA471/IFCC)10
against which ScysC-assays could be calibrated, and
only very recently a candidate isotope dilution mass spec-
trometry method for cystatin C was presented and canCLINICAL SUMMARY
 The pediatric form of the Full Age Spectrum (FAS) equation
offers an alternative to the bedside Schwartz equation,
allowing automatic reporting of estimated glomerular
filtration rate (eGFR) since height is not necessary, and
mostly not available in the clinical laboratory.
 Combining standardized biomarkers increases the
prediction performance of eGFR equations for children,
reaching P10 z 45% and P30 z 90%. The bivariate
Schwartz equation and the multiplicative form of the FAS
equation are very similar.
 eGFR equations perform best in the population for whom
they were originally designed for, with preference for FAS
in healthy and mildly kidney diseased children
(GFR . 60 mL/min/1.73 m2) and with preference for
Schwartz in the kidney diseased children (GFR , 60 mL/
min/1.73 m2).
 We recommend that clinical laboratories should report
serum creatinine along with the height-independent FAS
prediction. Clinicians would use the height-dependent
FAS, and in case, the FAS eGFR is , 60 mL/min/1.73 m2,potentially serve as gold
standard method.11 Part of
the data in this study were
obtained with the calibrated
particle enhanced turbidi-
metric (PETIA, Tina quant)
assay of Roche, and part of




Calibration of cystatin C as-
says is as essential as for
Scr. Although there is still
work to do, as the current
certiﬁed material is about
ﬁve times higher than the
“normal” cystatin C values,
and only a one-point calibra-
tion is applied, it has been
shown that calibration
against the certiﬁed material
reduces variability and in-
creases accuracy.11-12use the Schwartz equation to obtain a second estimate of
GFR.MULTIPLE BIOMARKER
EQUATIONS
To our knowledge, there are only a very limited number of
combined Scr and ScysC-based eGFR equations for chil-
dren available that were obtained with reference to
IDMS traceable Scr and the certiﬁed standard for ScysC.
Although the best performing combined Schwartz equa-
tion was based on height, Scr, ScysC, blood urea nitrogen,
and gender, ScysC was not calibrated against the certiﬁed
standard when this equation was derived. This complex
Schwartz formula was originally published in 2009 using
turbidimetric ScysC values13 and was
eGFR ¼ 39:1 ðHt=ScrÞ0:516 ð1:8=CysCÞ0:294
ð30=BUNÞ0:169 1:099male ðHt=1:4Þ0:188The equation was reevaluated using immunonephelo-
metric ScysC values14 and was
eGFR ¼ 39:8 ðHt=ScrÞ0:456 ð1:8=CysCÞ0:418
ð30=BUNÞ0:079 1:076male ðHt=1:4Þ0:179
This Chronic Kidney Disease in Children Cohort Study
equation showed high accuracy and precision and mini-
mal bias in the Chronic KidneyDisease in Children Cohort
Study population, that is, this equation worked well in
children with CKD in a range of GFR from 15 to 75 mL/
min/1.73 m2. Conﬁrmation of the utility of this equation
is desirable in other populations of children (healthy and
diseased), but both equations suffer from the drawback
that ScysC has not been calibrated against the certiﬁed
standard, and since its original publication in 2009 and
republication in 2012, only a limited number of externalAdv Chronicvalidation studies for both
equations have been pub-
lished.15-21 We have used
the univariate (for Scr or
ScysC) and bivariate form
(with both Scr and ScysC)
of the above equation
(without the blood urea
nitrogen information) on
our data to compare it with
alternative equations. An
overview of the equations
used in this study is given
in Table 1.
In the following section, we
restrict ourselves to equa-
tions that were derived and
are applicable to standard-
ized biomarkers Scr and
ScysC.
Recently, Pottel and col-
leagues22-23 published the
FAS equation to estimate
GFR from Scr and/or ScysC,
or from the combination of
both biomarkers. The
pediatric form (which is
actually valid between 2and 40 years of age) of the Scr-based FAS equation is a
very simple equation:
FAScrea ¼ 107:3=½Scr=Qcrea
The form of this equation follows from modeling the
data of Piepsz24-25 and establishing a plateau value of
107.3 mL/min/1.73 m2 for healthy children between 2
and 15 years of age. As Scr raises linearly with age in
that age period and following the correlation between
GFR and the reciprocal of creatinine, Pottel and
colleagues26 normalized Scr to make it independent of
age (and sex) and established a direct relationship betweenKidney Dis. 2018;25(1):57-66
Table 1. Overview of Equations Used in This Comparison Study, With Reference to the Original Publication
Name (Reference) Equation
Schwartzbed
2 0.413 Ht/Scr (Scr in mg/dL, Ht in cm)
Schwartzcrea
14 42.3 (Ht/Scr)0.780 (Scr in mg/dL, Ht in m)
SchwartzcysC
14 40.9 (1.8/ScysC)0.931 (ScysC in mg/L)
Schwartzcombi
14 41.6 (Ht/Scr)0.443 (1.8/CysC)0.479 (Scr in mg/dL, ScysC in mg/L, Ht in m)
FAScrea
26-28 107.3/[Scr/Qcrea] with Qcrea (mg/dL) function of age (Table 2) or using
Qcrea(Age) ¼ 0.21 1 0.057 3 Age 2 0.0075 3 Age2 1 0.00064 3 Age3 2 0.000016 3 Age4 for boys
Qcrea(Age) ¼ 0.23 1 0.034 3 Age 2 0.0018 3 Age2 1 0.00017 3 Age3 2 0.0000051 3 Age4 for girls
FAScrea(Ht)
28 107.3/[Scr/Qcrea] with Qcrea (mg/dL) function of height (Table 2) or using
Qcrea(height) ¼ 3.94 2 13.4 3 Ht 1 17.6 3 Ht2 2 9.84 3 Ht3 1 2.04 3 Ht4 (Ht in m)
FAScysC













LM-REV29 LM-REV ¼ exp[X – 0.0158 3 Age 1 0.438 3 ln(Age)] with
X ¼ 2.50 1 0.0121 3 (150 2 Scr), for females and Scr ,150 mmol/L
X ¼ 2.50 2 0.926 3 ln(Scr/150), for females and Scr $150 mmol/L:
X ¼ 2.56 1 0.00968 3 (180 2 Scr), for males and Scr,180 mmol/L:
X ¼ 2.56 2 0.926 3 ln(Scr/180), for males, and Scr $180 mmol/L
Conversion: Scr (mg/dL) ¼ Scr(mmol/L)/88.4
CAPA30 130 3 ScysC21.069 3 age20.117 2 7 (ScysC in mg/L)
Abbreviations: CAPA, Caucasian Asian Pediatric Adult; FAS, Full Age Spectrum; LM-REV, revised Lund-Malm€o; Scr, serum creatinine.
eGFR Equations for Children 59the value of 107.3 mL/min/1.73 m2 and the reciprocal of
this normalized Scr. When a child has a Scr level equal to
the Qcrea value, which is deﬁned as the mean or median
Scr value of the 1-year age-speciﬁc distribution of
Scr of healthy children, then Scr/Qcrea ¼ 1 and
eGFR ¼ 107.3 mL/min/1.73 m2, the mean GFR value for
healthy children. The concept of the FAS equation is that
it essentially matches mean Scr levels with mean GFR
levels in healthy populations. The pediatric FAS equation
was ﬁrst published in 201227 and extended by Hoste and
colleagues28 to adolescents in 2015 and is now extended
to the full age spectrum.22 It has been shown that this
concept also applies for other biomarkers: Scr/Qcrea can
be replaced by ScysC/QcysC or a combination of both bio-
markers, for example, the average of both normalized bio-
markers: (Scr/Qcrea1 ScysC/QcysC)/2. In case of ScysC, the
normalization factor QcysC ¼ 0.82 mg/L23 (Table 1).
Other eGFR equations have been developed for children,
but none of them combines standardized Scr and ScysC in
one equation for children. However, it has recently been
shown that combining the Scr-based revised Lund-Malm€o
(LM-REV) equation29 with the ScysC-based CAPA equa-
tion30 also shows higher accuracy and precision than any
single biomarker–based equation.31
The LM-REV equation and CAPA equation are also pre-
sented in Table 1.
Combining LM-REV with CAPA simply means to take
the mean of both equations: (LM-REV 1 CAPA)/2.
Contrary to the FAS equation, which is based on the
concept that mean normalized Scr matches mean GFR,
the LM-REV and CAPA equations, like all other eGFR
equations, have been derived from statistical modeling
of measured GFR data against Scr (or ScysC) and demo-
graphic variables.Adv Chronic Kidney Dis. 2018;25(1):57-66In the following sections, we focus on the popular
bedside Schwartz equation and compare it to the pediatric
FAS equation, ﬁnd out the beneﬁts of using combined
biomarkers as such and combined biomarker equations,
by comparing the combined Schwartz equation, the com-
bined FAS equation, and the combination of Lund-Malm€o
and CAPA to measured GFR.
COMPARING THE SIMPLE BEDSIDE Scr-BASED
SCHWARTZ WITH FAS
The normalization factor Qcrea in the pediatric FAS equa-
tion can be obtained in two different ways: (1) Qcrea can
be considered as the mean Scr value of the age-speciﬁc
distribution of healthy children, but (2) Qcrea can also
be matched to the height of the child, by use of growth
curves (Table 2). Table 2 should be interpreted with
caution, as these values have been determined in a
Belgian population of healthy children. The mean Scr
values were obtained from a large hospital database9
which was subdivided according to age/gender. For
each 1-year age period, the Scr values of healthy children
were selected and the mean/median (which is the same
when the distribution is Gaussian) is presented as Qcrea
in Table 2. National Belgian growth curves32 were used
to match age with mean height of the children. To esti-
mate GFR from Scr, there are two possibilities: either
the Qcrea corresponding to the age of the child can be
considered or the Qcrea corresponding to the height of
the child can be chosen, which are not necessarily the
same for a child at a speciﬁc age with a speciﬁc height.
This is especially true during adolescence, where children
may be variable in height at the same age. Height is
probably a better indicator for muscle mass and thus
for the corresponding Scr value. This is also the reason
Table 2. Mean or Median Scr Values for Healthy Children (Qcrea) in
mg/dL, According to Age or Height (Ht)















































RelaƟonship between bedside Schwartz and FAS
Figure 1. Plot of 107.3 3 Qcrea/L vs age should be equal to
0.413, the constant of the Schwartz equation in case
FAScrea¼ Schwartzbed. The solid horizontal line corresponds
to 0.413, the Schwartz constant; the horizontal dotted line
corresponds to 0.368, the value used in the modified
Schwartz-Lyon equation for children below 13 years of
age. The circles are calculated from Table 2, using the Qcrea
values obtained from healthy Belgian children, and height
(L) is obtained as the median from the Belgian national
growth curves (for healthy children). Abbreviation: FAS,
Full Age Spectrum.
Pottel et al60why the FAS equation with Qcrea(height) gives better pre-
dictions than the FAS equation with Qcrea(Age).
22,33
Hoste and colleagues28 have modeled the Qcrea values
against age, and Qcrea against height, to allow interpola-
tion (to predict Qcrea for values in between the values in
Table 2), resulting in 4th degree polynomials (Table 1).
Note that there are twopolynomials forQcrea(Age) due to
the difference between adolescent males and females, that
is, adolescentmales gainmusclemass in amuch fasterway
than females in this age period, starting from
Qcrea ¼ 0.61 mg/dL at 14 years of age, on average, and
reaching the average plateau value of 0.90mg/dL, whereas
females only reach the value of 0.70 mg/dL. Qcrea(height)
could be modeled in one 4th degree polynomial, showing
that height is a better surrogate than age for gaining mus-
cle mass, as it is independent of gender.
The pediatric part of the FAS equation can be rewritten as
FAScrea ¼ 107.33Qcrea/Scr. As the Schwartz equation also
estimates GFR, it follows that 107.33Qcrea¼ 0.4133 L. As
both equations have been derived in a totally different way
and from totally different data sets (Pottel used healthy
children and Schwartz used growth-retarded kidney
diseased children), the discrepancy between both equa-
tions should not be surprising. Figure 1 presents the plot
of 107.3 3 Qcrea/L vs age, with the data obtained from
Table 2, which should correspond to the coefﬁcient in the
Schwartz Equation (0.413) in case the FAS equation andSchwartz equation are equal. This plot shows that for chil-
dren up to 14 years of age, the results are indeed very
similar, but the difference is large for adolescents. For chil-
dren up to 14 years of age, small adaptations of the coefﬁ-
cients (of the Schwartz or FAS equation) can solve the
discrepancy: for example, a perfect match between the
FAS equation and the Schwartz equation would be ob-
tained if 0.413 is replaced by 0.385 (a difference of about
7%), or, if 107.3 is replaced by 115, or combinations ofmod-
iﬁcations. Anyhow, this analysis shows that the FAS and
Schwartz equations are essentially approximately the
same for children up to 14 years of age, when height in
the Schwartz equation is matched with the Q-value at
the same age (Table 2). The FAS equation has the advan-
tage that it can also be appliedwhen height is not available.
For female and male adolescents, there is a clear devia-
tion from the Schwartz coefﬁcient of 0.413, showing that
Schwartz and FAS deviate strongly for these children.
Indeed, others have shown that modiﬁcations to the
Schwartz equation are required. The Schwartz-Lyon equa-
tion is a modiﬁcation of the original Schwartz equation
derived by De Souza and colleagues.34 She found that
for girls and boys ,13 years, the coefﬁcient is 0.368 and
0.413 for boys $13 years. Based on this analysis, we may
conclude that the Schwartz coefﬁcient is probably a little
bit too high for (healthy) younger children and needs to
be optimized for adolescents, which is not surprising since
the data used by Schwartz only contained children up to
16 years of age.
In Figure 2,weplotted 107.33Qcrea/L vs the height of the
child, showing that the Schwartz coefﬁcient of 0.413 (or
0.385, according to FAS) is more or less valid for children
with height ,165 cm, which is mostly true for girls and
boys ,13 years, corresponding to the Schwartz-Lyon
modiﬁcation. Male adolescents are clearly a much more
difﬁcult population to model in a simple eGFR equation,

















Figure 3. ScysC/QcysC against Scr/Qcrea for n¼ 845measure-
ments from children between 2 and 18 years of age. The di-
agonal line is the identity line. The horizontal and vertical
lines correspond to the reference interval (0.67–1.33) of the
normalized biomarker, which may be considered as the


















RelaƟonship between bedside Schwartz and FAS
Figure 2. Plot of 107.33 Qcrea/L vs height (cm). The horizon-
tal solid line corresponds to the Schwartz coefficient of
0.413. Up to a height of 165 cm, the coefficient is approxi-
mately constant, but for adolescents with height .165 cm
(mostly boys), the coefficient should be higher, according
to the FAS equation. Abbreviation: FAS, Full Age Spectrum.
eGFR Equations for Children 61FAS, and Schwartz-Lyon. The advantage of the FAS equa-
tion over all other equations is that it makes the transition
between children and adults, as the pediatric FAS equation
is part of the more general FAS equation which is valid for
all ages. Both the Schwartz equation and Schwartz-Lyon
equation suffer from the drawback that they really differ
from adult equations at the transition age of 18 years.
For example, for a value of Scr ¼ 0.85 mg/dL (the average
value for an 18-year old adolescentmale, see Table 2) and a
height of 179 cm, Schwartz and Schwartz-Lyon predict an
eGFR¼ 87mL/min/1.73m2which is very low compared to
the eGFR-prediction by the CKD-EPI-equation,35 which
gives 124.3 mL/min/1.73 m2 for the same adolescent
male. The FAS equation predicts 107.3 mL/min/1.73 m2
at the average Scr value for the average height at the age
of 18 years.
COMBINING BIOMARKERS Scr AND ScysC
As the form of the FAS equation is valid for both normal-
ized biomarkers, it is easy to understand that the same esti-
mated GFR can only be obtained from both biomarkers,
when Scr/Qcrea ¼ ScysC/QcysC¼ (Scr/Qcrea 1 ScysC/
QcysC)/2. It also follows that the ratio of FAScysC/FAScrea
is equal to the (reciprocal) ratio of the normalized bio-
markers: [Scr/Qcrea]/[ScysC/QcysC]. Therefore, when the
estimated GFR from Scr (FAScrea) differs signiﬁcantly
from the estimated GFR from ScysC (FAScysC), this is an
immediate consequence of the difference between normal-
ized biomarkers.36-37
To demonstrate the above reasoning, we plotted ScysC/
QcysC against Scr/Qcrea in Figure 3 for n ¼ 845 measure-
ments of children between 2 and 18 years of age. ThisTable 3. Overview of the Mean Measured GFR, Mean Scr, Mean ScysC
“Normal” Biomarker Values
n, Total n, “normal” Age (y) Mean Age (y)
246 135 (2-10) 6.5 0.9
599 245 (10-18) 14.7 0.9
Abbreviations: CI, confidence interval; GFR, glomerular filtration rate; m
Adv Chronic Kidney Dis. 2018;25(1):57-66data set has been previously described36-37 and contains
serial measurements of n ¼ 368 children, a data set with
unique measurements only, used and described
before15-16 to compare eGFR equations. It has been
shown previously that both normalized and rescaled
biomarkers share the same common reference interval of
(0.67-1.33).23,36-37
Avery simple approach to deﬁne or diagnose kidney dis-
ease in children would be to consider whether the normal-
ized biomarker is within the reference interval of
(0.67-1.33) (Table 3). We applied that rule to a cohort of
845 measurements on children aged between 2 and
18 years. Children with biomarker values within the refer-
ence interval have indeed mean mGFR values which are
not different from 107.3 mL/min/1.73 m2, the value pre-
dicted by the FAS equation at the mean Scr ¼ Qcrea or
ScysC ¼ QcysC level.
Table 3 also shows that Scr/Qcrea is approximately equal
to “1,” the mean Scr value for healthy children. The devia-
tion by 7% from “1” for ScysC/QcysC might be due to the
not optimal normalization factor of 0.82 mg/L that has
been used or it may be due to the speciﬁc data set, as
all children were from nephrology clinics with speciﬁc un-
derlying (kidney) pathologies. We can also not rule out
assay-related reasons for this deviation (calibration issues,
differences between Roche and Siemens assays).
We deﬁned the kidney function as “abnormal” when the
normalized biomarker was greater than 1.33 and as
“normal” when the normalized biomarker was less than
or equal to 1.33. We then performed ROC analysis, using
measured GFR as the conﬁrmatory test (Table 4). This(With 95% CI) for the n ¼ 380 Measurements of Children With Both
Scr/Qcrea ScysC/QcysC mGFR (mL/min/1.73 m
2)
9 (0.96–1.02) 1.07 (1.05–1.10) 107.0 (103.2–110.9)
9 (0.97–1.01) 1.07 (1.05–1.09) 104.6 (101.7–107.5)
GFR, measured GFR; Scr, serum creatinine.
Table 4. ROC Analysis
Marker Age Group # Normal # Abnormal Threshold AUC SE S (%)
Scr/Qcrea 2-10 170 76 79.0 0.937 0.016 78.9
10-18 358 241 72.0 0.940 0.009 80.5
ScysC/QcysC 2-10 158 88 78.0 0.873 0.023 65.9
10-18 290 309 78.0 0.910 0.012 77.0
Combined 2-10 159 87 81.0 0.931 0.016 80.4
10-18 318 281 79.8 0.961 0.007 86.8
Abbreviations: mGFR, measured GFR; Scr, serum creatinine.
“Abnormal” is defined asmarker.1.33 and “normal” as#1.33. mGFR is considered as the confirmatory test. The “threshold” is the value of
mGFR corresponding with the most optimal sensitivity at a specificity of 90%. AUC is the area under the ROC curve (an ideal ROC curve has
AUC ¼ 1) and SE is the standard error on the AUC. S (%) is the sensitivity at the reported threshold, corresponding to a specificity of 90%;
“combined” means the average of both rescaled biomarkers.
Pottel et al62way of working is turning things around, as GFR is nor-
mally used to deﬁne kidney status. However, this ROC
analysis demonstrates that childrenwith biomarkerswithin
the reference interval have mGFR values mostly above
80 mL/min/1.73 m2, corresponding to a speciﬁcity of 90%
and a sensitivity of more than 80% (in case of combining
both biomarkers). This ﬁnding conﬁrms the earlier report
of Pottel and colleagues38 that abnormal GFR starts below
75 mL/min/1.73 m2 for children. The upper limit of the bio-
marker’s reference interval (1.33) would correspond to
FAS ¼ 107.3/1.33 ¼ 81 mL/min/1.73 m2. According to the
FAS concept, this value could be considered as the lower
limit for the eGFR reference interval. We therefore
compared the effect of the threshold of 60 mL/min/
1.73 m2 with 81 mL/min/1.73 m2 on the consistency with
the biomarker reference interval and found that there was
about 10%more agreement (p, 0.0001)when the threshold
of 81mL/min/1.73m2wasused (Table 5). This demonstrates
that, in the case of children, the reference interval of (0.67-
1.33) can be used to diagnose healthy kidney status, corre-
sponding with a GFR threshold of 81 mL/min/1.73 m2.
PREDICTION PERFORMANCE OF COMBINED eGFR
EQUATIONS
In this section, we focus on eGFR equations that use both
Scr and ScysC for children. We compare the combined
Schwartz equation (which has not been designed for stan-
dardized ScysC) with the combined FAS equation and
with the combination of the LM-REVand CAPA equations
that are based on the single biomarkers.31
To compare the performance of different eGFR equa-
tions, we took out all serial measurements in the previousTable 5. Frequency of Patients With Normal/Abnormal Biomarkers in t
Age
Group















2-10 0 159 14 145 159 28 59 67
10-18 1 317 38 280 318 152 129 245
Abbreviation: mGFR, measured GFR; Scr, serum creatinine.
% Agreement ¼ agreement between kidney status defined as healthy or
1.33 and once based on the measured GFR with threshold 60 or 81 mL/data set, resulting in n ¼ 368 children, for whom we used
the ﬁrst measurement only. We have published the perfor-
mance results of different equations before,22-23 but we
here add the Scr-based LM-REV equation and the combi-
nation of LM-REV with the ScysC-based CAPA equation
(see Table 6). We also present the results of the univariate
and bivariate Schwartz equations, using Scr and ScysC in
Table 7.
The performance of the FAS equation and LM-REVequa-
tion is relatively similar (see Table 6) overall, but LM-REV
performed much worse than FAS in the ,60 mL/min/
1.73 m2 subgroup. The univariate and bivariate Schwartz
equation performed worse than the other combined equa-
tions in the$60 mL/min/1.73 m2 subgroup, but much bet-
ter than the other equations in the ,60 mL/min/1.73 m2
subgroup. This demonstrates that both FAS and Schwartz
perform best in the subgroups for which they were origi-
nally designed for. It may also suggest that “one” equation
to predict GFR in both healthy and diseased children will
never be as accurate as separate equations, speciﬁcally de-
signed for either of both groups.
To ﬁnd an explanation for these differences, we plotted
the univariate Scr-based equations for Scr/Qcrea ¼ 1, Scr/
Qcrea ¼ 0.67 and 1.33, the midpoint, and lower and upper
limits of the Scr/Qcrea reference interval (Fig. 4). We did the
same for the univariate ScysC-based Schwartz, FAS equa-
tion, and the CAPA equation, again at midpoint (0.82 mg/
L) and the reference interval limits (Fig. 5).
For children with mGFR ,60 mL/min/1.73 m2, LM-REV
does not show good performance, as seen from Table 6,
mainly because the estimated GFR is much too high
(bias ¼ 16.6 mL/min/1.73 m2) which can also be observedhe Subgroups Defined by mGFR













20 87 246 76.0 86.2 0.0008
36 281 599 78.3 87.6 , 0.0001
diseased, once based on the biomarker combination with threshold
min/1.73 m2.
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Table 6. Children n ¼ 368 (Age # 18 Years)
All (n ¼ 368) Scr-Based eGFR ScysC-Based eGFR Combined Scr/ScysC-Based eGFR
mGFR ¼ 89.2 FAScrea FAScrea(Ht) Schwartzcrea LM-REV FAScysC CAPA FAScombi FAScombi(Ht) LM-REV 1 CAPA
eGFR – mGFR 12.3 (7.7; 17.0) 3.8 (0.9; 6.6) 11.1 (8.1; 14.1) 2.9 (0.7; 5.0) 25.1 (27.2; 23.1) 0.3 (22.0; 2.6) 0.9 (20.9; 2.7) 22.2 (24.0; 20.4) 1.6 (20.2; 3.3)
eGFR/mGFR 1.17 (1.12; 1.21) 1.06 (1.04; 1.09) 1.15 (1.12; 1.18) 1.10 (1.07; 1.10) 0.98 (0.96; 1.01) 1.03 (1.00; 1.05) 1.05 (1.03; 1.07) 1.01 (0.99; 1.03) 1.06 (1.04; 1.08)
RMSE 47.0 (27.2; 67.6) 28.3 (11.4; 39.2) 31.3 (13.9; 42.9) 21.0 (18.6; 23.2) 20.4 (17.9; 22.5) 22.3 (20.0; 24.3) 17.5 (15.1; 19.7) 17.6 (15.5; 19.7) 17.1 (15.1; 18.9)
Lin’s CCC 0.43 (0.36; 0.49) 0.65 (0.59; 0.70) 0.63 (0.57; 0.68) 0.68 (0.63; 0.72) 0.73 (0.68; 0.77) 0.74 (0.68; 0.78) 0.81 (0.77; 0.84) 0.80 (0.77; 0.84) 0.80 (0.76; 0.83)
P10 (%) 32.3 (27.5; 37.1) 42.7 (37.6; 47.7) 40.5 (35.5; 45.5) 31.5 (26.8; 36.3) 40.5 (35.5; 45.5) 36.4 (31.5; 41.4) 44.6 (39.5; 49.7) 43.2 (38.1; 48.3) 45.1 (40.0; 50.2)
P30 (%) 78.3 (74.0; 82.5) 84.5 (80.8; 88.2) 79.9 (75.8; 84.0) 77.4 (73.2; 81.7) 86.1 (82.6; 89.7) 76.6 (72.3; 81.0) 90.8 (87.8; 93.7) 92.1 (89.4; 94.9) 88.6 (85.3; 91.9)
mGFR , 60 mL/min/1.73 m2 (n ¼ 57)
mGFR ¼ 45.2 FAScrea FAScrea(Ht) Schwartzbed LM-REV FAScysC CAPA FAScombi FAScombi (Ht) LM-REV 1 CAPA
eGFR – mGFR 12.5 (10.0; 15.1) 5.1 (3.0; 7.2) 8.8 (6.5; 11.0) 16.6 (13.6; 19.7) 6.2 (3.1; 9.3) 3.3 (20.4; 7.1) 8.3 (6.2; 10.5) 5.0 (2.9; 7.1) 10.0 (7.3; 12.7)
eGFR/mGFR 1.31 (1.24; 1.37) 1.14 (1.08; 1.20) 1.22 (1.16; 1.29) 1.39 (1.31; 1.48) 1.17 (1.09; 1.25) 1.10 (1.01; 1.19) 1.21 (1.15; 1.27) 1.14 (1.08; 1.20) 1.25 (1.17; 1.32)
RMSE 15.8 (12.7; 18.4) 9.4 (7.5; 10.9) 12.2 (9.7; 14.2) 20.2 (17.0; 23.0) 13.1 (9.8; 15.7) 14.3 (10.4; 17.3) 11.6 (9.4; 13.5) 9.3 (7.3; 11.0) 14.3 (11.1; 16.8)
Lin’s CCC 0.44 (0.29; 0.56) 0.66 (0.50; 0.77) 0.55 (0.40; 0.68) 0.36 (0.23; 0.48) 0.48 (0.29; 0.64) 0.47 (0.28; 0.63) 0.56 (0.41; 0.69) 0.65 (0.49; 0.77) 0.50 (0.35; 0.63)
P10 (%) 10.5 (2.3; 18.7) 45.6 (32.3; 58.9) 36.8 (23.9; 49.8) 14.0 (4.7; 23.3) 24.6 (13.0; 36.1) 29.8 (17.6; 42.1) 28.1 (16.0; 40.1) 38.6 (25.6; 51.6) 26.3 (14.5; 38.1)
P30 (%) 63.2 (50.2; 76.1) 71.9 (59.9; 84.0) 71.9 (59.9; 84.0) 38.6 (25.6; 51.6) 68.4 (56.0; 80.9) 66.7 (54.0; 79.3) 71.9 (59.9; 84.0) 80.7 (70.1; 91.3) 66.7 (54.0; 79.3)
mGFR $ 60 mL/min/1.73 m2 (n ¼ 311)
mGFR ¼ 97.3 FAScrea FAScrea(Ht) Schwartzbed LM-REV FAScysC CAPA FAScombi FAScombi (Ht) LM-REV 1 CAPA
eGFR – mGFR 12.3 (6.8; 17.8) 3.5 (0.1; 6.9) 11.5 (8.0; 15.1) 0.4 (22.0; 2.7) 27.2 (29.5; 25.0) 20.2 (22.9; 2.4) 20.5 (22.5; 1.6) 23.5 (25.6; 21.4) 0.1 (21.9; 2.0)
eGFR/mGFR 1.14 (1.09; 1.19) 1.05 (1.02; 1.08) 1.13 (1.10; 1.17) 1.04 (1.02; 1.06) 0.95 (0.93; 0.97) 1.02 (0.99; 1.04) 1.01 (0.99; 1.03) 0.98 (0.96; 1.00) 1.03 (1.01; 1.05)
RMSE 50.7 (10.5; 77.5) 30.5 (10.1; 42.0) 33.7 (12.7; 45.9) 21.2 (18.3; 23.7) 21.5 (18.8; 23.8) 23.5 (21.0; 25.8) 18.4 (13.5; 20.8) 18.8 (16.3; 21.0) 17.6 (15.3; 19.6)
Lin’s CCC 0.29 (0.22; 0.37) 0.50 (0.41; 0.57) 0.48 (0.40; 0.55) 0.52 (0.44; 0.59) 0.59 (0.52; 0.65) 0.60 (0.52; 0.66) 0.71 (0.65; 0.76) 0.69 (0.62; 0.74) 0.68 (0.62; 0.73)
P10 (%) 36.3 (31.0; 41.7) 42.1 (36.6; 47.6) 41.2 (35.7; 46.7) 34.7 (29.4; 40.0) 43.4 (37.9; 48.9) 37.6 (32.2; 43.0) 47.6 (42.0; 53.2) 44.1 (38.5; 49.6) 48.6 (43.0; 54.1)
P30 (%) 81.0 (76.6; 85.4) 86.8 (83.0; 90.6) 81.4 (77.0; 85.7) 84.6 (80.5; 88.6) 89.4 (85.9; 92.8) 78.5 (73.9; 83.1) 94.2 (91.6; 96.8) 94.2 (91.6; 96.8) 92.6 (89.7; 95.5)
Abbreviations: CAPA, Caucasian Asian Pediatric Adult; eGFR, estimated glomerular filtration rate; FAScrea, Full Age Spectrum eGFR equation, based on Q(Age); FAScrea(Ht), FAS
equation based on Q(height); Lin’s CCC, Lin’s concordance correlation coefficient; LM-REV, revised Lund-Malm€o; mGFR, measured GFR; P10/P30, % within 10%/30% of mGFR;
RMSE, root mean square error; Scr, serum creatinine; Schwartzbed, updated bedside Schwartz equation for children (Scr-base ¼ 0.413 Ht/Scr). FAScysC, full age spectrum eGFR
equation based on cystatin C (Table 1); Schwartzcrea, creatinine based revised Schwartz equation (Table 1), FAScombi, combined Scr/ScysC FAS equation (Table 1);
FAScombi(Ht), combined Scr/ScysC FAS(height) equation (Table 1).













































Table 7. Children n ¼ 368 (Age # 18 Years)
All (n ¼ 368)
mGFR ¼ 89.2 Schwartzcrea SchwartzcysC Schwartzcombi FASMult
eGFR – mGFR 25.7 (27.8; 23.5) 221.6 (223.7; 219.6) 210.1 (212.0; 28.3) 21.5 (23.4; 0.4)
eGFR/mGFR 0.98 (0.96; 1.00) 0.79 (0.78; 0.81) 0.92 (0.90; 0.94) 1.02 (1.00; 1.04)
RMSE 21.9 (16.3; 26.3) 29.6 (27.0; 32.1) 20.5 (18.0; 22.8) 18.5 (15.3; 21.2)
Lin’s CCC 0.70 (0.64; 0.74) 0.49 (0.44; 0.54) 0.72 (0.68; 0.76) 0.79 (0.75; 0.83)
P10 (%) 45.1 (40.0; 50.2) 16.0 (12.3; 19.8) 40.5 (35.5; 45.5) 44.3 (39.2; 49.4)
P30 (%) 89.9 (86.9; 93.0) 68.8 (64.4; 73.5) 90.5 (87.5; 93.5) 91.6 (88.7; 94.4)
mGFR , 60 mL/min/1.73 m2 (n ¼ 57)
mGFR ¼ 45.2 Schwartzcrea SchwartzcysC Schwartzcombi FASMult
eGFR – mGFR 6.7 (4.7; 8.6) 22.4 (25.0; 0.2) 2.4 (0.4; 4.4) 5.3 (3.2; 7.5)
eGFR/mGFR 1.19 (1.12; 1.25) 0.98 (0.91; 1.04) 1.08 (1.03; 1.14) 1.15 (1.09; 1.21)
RMSE 9.8 (7.7; 11.6) 10.0 (7.5; 12.0) 7.7 (5.8; 9.3) 9.5 (7.5; 11.2)
Lin’s CCC 0.59 (0.43; 0.71) 0.55 (0.35; 0.71) 0.71 (0.55; 0.81) 0.64 (0.48; 0.76)
P10 (%) 45.6 (32.3; 58.9) 36.8 (23.9; 49.8) 50.9 (37.5; 64.3) 38.6 (25.6; 51.6)
P30 (%) 78.9 (68.0; 89.9) 86.0 (76.7; 95.3) 87.7 (78.9 96.5) 80.7 (70.1; 91.3)
mGFR $ 60 mL/min/1.73 m2 (n ¼ 311)
mGFR ¼ 97.3 Schwartzcrea SchwartzcysC Schwartzcombi FASMult
eGFR – mGFR 27.9 (210.4; 25.5) 225.2 (227.4; 223.0) 212.4 (14.5; 210.4) 22.7 (24.9; 20.5)
eGFR/mGFR 0.94 (0.92; 0.96) 0.76 (0.75; 0.78) 0.89 (0.88; 0.91) 0.99 (0.97; 1.01)
RMSE 23.4 (17.2; 28.3) 32.0 (29.1; 34.5) 22.1 (19.3; 24.6) 19.7 (16.1; 22.7)
Lin’s CCC 0.55 (0.47; 0.62) 0.33 (0.27; 0.38) 0.57 (0.51; 0.63) 0.67 (0.60; 0.73)
P10 (%) 45.0 (39.5; 50.6) 12.2 (8.6; 15.9) 38.6 (33.1; 44.0) 45.3 (39.8; 50.9)
P30 (%) 92.0 (88.9; 95.0) 65.6 (60.3; 70.9) 91.0 (87.8; 94.2) 93.6 (90.8; 96.3)
Abbreviations: eGFR, estimated glomerular filtration rate; Lin’s CCC, Lin’s concordance correlation coefficient; mGFR, measured GFR; P10/
P30, % within 10%/30% of mGFR; RMSE, root mean square error; Scr, serum creatinine.








Pottel et al64from Figure 4, where (mostly male) children between 4
and 15 years of age with Scr close to the lower limit of
the Scr reference interval have estimated GFR from LM-
REV mostly higher than estimated GFR from Schwartz





















Figure 4. Serum creatinine: comparison of the bedside
Schwartz equation (solid lines), the pediatric FAS (solid flat
horizontal lines), and LM-REV (dotted lines, separate for
males and females) for all ages, up to 18 years. The middle
curves correspond to Scr¼Q or Scr/Q¼ 1. The upper curves
correspond to Scr/Q ¼ 0.67, and the lower curves corre-
spond to Scr/Q ¼ 1.33. Data from Table 2 are used for the
simulation. Abbreviations: eGFR, estimated glomerular
filtration rate; FAS, Full Age Spectrum; LM-REV ¼ revised
Lund-Malm€o; Scr, serum creatinine.min/1.73 m2). Only 3 subjects in this cohort of n¼ 368 chil-
dren had Scr.150 mmol/L (or 150/88.4 mg/dL), indicating
that the switch in the LM-REV equation has only be
applied in 3 occasions. As both FAS and LM-REV overes-























Figure 5. Cystatin C: comparison of the univariate cystatin
C–based Schwartz equation (horizontal dotted lines), FAS
(horizontal solid lines), and CAPA (curved solid lines) for
all ages up to 18 years. The middle curves correspond to
ScysC ¼ Q or ScysC/Q ¼ 1. The upper curves correspond
to ScysC/Q ¼ 0.67, and the lower curves correspond to
ScysC/Q¼ 1.33. Q¼ 0.82mg/L is used for ages up to 18 years.
Abbreviations: CAPA, Caucasian Asian Pediatric Adult;
eGFR, estimated glomerular filtration rate; FAS, Full Age
Spectrum.
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eGFR Equations for Children 65much more than FAS, resulting in a much higher bias.
Overall, the updated simple bedside Schwartz equation
performs worse than FAS, but the new univariate Scr-
based Schwartz equation performs slightly better than
FAS. The ﬁgure also shows that LM-REV has a much
smaller variability than Schwartz or FAS, meaning that
all estimated GFR results will be much closer together
for LM-REV than for Schwartz or FAS. This theoretical
comparison shows that there is a totally different behavior
of LM-REV compared to Schwartz or FAS for children.
Due to the high imprecision of all eGFR equations, this dif-
ference will probably not be so obvious when real mGFR
data are used for the comparison, unless very large sample
sizes are evaluated. Also for adolescents, it is clear that all
equations perform differently.
For cystatin C, Schwartz and FAS are age independent,
while CAPA has a built-in age dependency. The cystatin
C–based Schwartz equation eGFR ¼ 40.9 (1.8/
ScysC)0.931 ¼ 70.7/ScysC0.931 and the cystatin C–based
FAS equation eGFR ¼ 107.3/[ScysC/0.82] ¼ 88.0/ScysC
deviate from each other, mainly due to the lead coefﬁcient
(70.7 vs 88.0) explaining why FAS predictions are always
greater than Schwartz predictions for the same value of
cystatin C. Therefore, it may be expected that the cystatin
C–based Schwartz equation is better suited for kidney
diseased children and the FAS equation gives better pre-
dictions in the healthy children subgroup. The CAPA
equation rather closely follows the FAS equation for
ScysC ¼ 0.82 and ScysC ¼ 0.82 3 1.33, except for very
young children (,10 years). The discrepancy between
both equations is largest for low ScysC values (lower
than 0.82 mg/L). Important to note is the inverse proﬁle
for CAPA vs LM-REV with age for very young children,
compensating each other when both equations are com-
bined. The CAPA equation shows an even larger vari-
ability (wider curves) than the FAS equation and much
larger than the LM-REV equation for the same values of
the normalized biomarkers.
The combined FAS equation has been published as 107.3
divided by the average of both normalized biomarkers.
An alternative (unpublished) version of the combined
FAS equation makes use of the multiplication of the bio-







. The results for this equation
are shown in Table 7. This multiplicative form of the FAS
equation is verymuch alike the combined Schwartz equa-
tion. Indeed, linear regression (through the origin) of the
height of the child (in m) and Qcrea from Table 2 (for chil-
dren aged # 14 years) gives: Qcrea ¼ 0.3588 3 L. Using
QcysC ¼ 0.82, the multiplicative form of the FAS equation
becomes: FASMult ¼ 583
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðL=ðScr x ScysCÞÞp where
58 ¼ 107.3 3 0.35880.5 3 0.820.5. The combined Schwartz
equation can be written as: Schwartz ¼ 55 [(L/Scr)0.443 3
(1/ScysC)0.479], where 55 ¼ 41.6 3 1.80.479. This shows
that both equations are essentially similar, with only
small differences in the coefﬁcients (58 vs 55, and 0.5 vs
0.443 and 0.479). Predictions of both equations for the
n ¼ 368 children result in a linear equation of
Schwartzcombi ¼ 0.823 3 FASMult 1 6.1 with correlationAdv Chronic Kidney Dis. 2018;25(1):57-66coefﬁcient of 0.98. Note, however, that correlation is not
the same as agreement, as can be seen from the linear
equations linking mGFR to eGFR, for FAS, we have
mGFR ¼ 0.97 3 FASMult 1 3.4 and for Schwartz, we
ﬁnd mGFR ¼ 1.16 3 Schwartzcombi2 2.7, both equations
having R2 ¼ 0.72. This shows that on the data at hand, the
slope deviates much more from the ideal slope of “1” for
Schwartzcombi than for FASMult. This proportional bias
might be a consequence of the noncalibrated cystatin C
results used to develop the Schwartz equation.
The combined equations reach P10 close to 45-50% and
P30 close to 90-95% in the.60 mL/min/1.73 m2 subgroup,
outperforming the single biomarker equations. All equa-
tions have difﬁculties to accurately predict GFR when
GFR ,60 mL/min/1.73 m2 (except the nonstandardized
ScysC-based Schwartz equation). However, we should
also realize that all children were from nephrology clinics
and only 57/368 ¼ 15% had GFR ,60 mL/min/1.73 m2,
meaning that it is not very common to see children with
GFR ,60 mL/min/1.73 m2.
CONCLUSIONS
The height-dependent FAS equation for children up to
14 years of age is essentially equal to the Schwartz equa-
tion, though be it with a 7% lower coefﬁcient (0.385 vs
0.413). The difference between both equations becomes
important for male adolescents. As the FAS equation al-
lows for the transition to adults, it seems that the Schwartz
equation predicts eGFR values that are too low for the
(healthy) adolescent population.
eGFR equations perform best in the population for
whom they were originally designed for, with preference
for Schwartz in the kidney diseased children (GFR
,60 mL/min/1.73 m2) and with preference for FAS in
healthy and less kidney diseased children (GFR .60 mL/
min/1.73 m2).
Biomarkers can be used as such to detect kidney disease
when they are outside the reference interval, consistent
with a threshold for mGFR for children of about 80 mL/
min/1.73 m2.
Finally, the combination of biomarkers shows improved
prediction performance as compared to single biomarker
equations. The multiplicative form of the FAS equation is
very similar to the bivariate Schwartz equation.
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